China NMPA Registration of In Vitro Diagnostic Reagents (IVDs) Whitepaper

China NMPA Registration of In Vitro Diagnostic Reagents (IVDs) Whitepaper

China represents one of the world’s most dynamic and strategically important markets for in vitro diagnostics (IVDs). Demand for advanced diagnostic technologies continues to grow as healthcare infrastructure expands, hospitals upgrade laboratory capabilities, and precision medicine initiatives accelerate across the country.

However, manufacturers seeking to introduce IVD products into the Chinese market must comply with the regulatory requirements of the National Medical Products Administration (NMPA). This whitepaper outlines the regulatory framework governing IVD registration in China and explains the pathways, technical requirements, and lifecycle obligations manufacturers must consider when entering this market.

Why This Topic Matters

China’s IVD market is expanding rapidly, supported by increasing healthcare demand, hospital infrastructure upgrades, and national policies encouraging medical innovation. Recent registration statistics illustrate this growth.

In 2024, 13,133 medical devices including IVDs were successfully registered in China, while 13,828 applications were accepted for review by the NMPA. In 2025, approvals increased further to 14,187 registrations, with 14,647 applications accepted for review.

At the same time, China’s regulatory system has evolved from focusing solely on pre-market approval toward a broader whole-of-lifecycle supervision model, emphasizing post-market surveillance, traceability, and regulatory accountability for both domestic and overseas manufacturers.

For international manufacturers, successful entry into China requires not only obtaining product approval, but also implementing long-term regulatory and compliance strategies.

What You Will Learn in This Whitepaper

This whitepaper provides an overview of regulatory requirements for IVD manufacturers seeking market access in China.

Key topics include:

• The regulatory framework governing IVD approvals in China
• The role of Chinese regulatory authorities responsible for medical device oversight
• Classification systems used for in vitro diagnostic reagents
• Available registration pathways for foreign manufacturers
• Documentation, testing, and clinical evidence requirements
• The technical review and approval process
• Post-market compliance obligations throughout the product lifecycle.

Regulatory Framework for IVDs in China

The regulation of in vitro diagnostics in China is overseen by a structured regulatory system involving several national authorities.

Key organizations include:

• State Administration for Market Regulation (SAMR) — responsible for national market supervision, standardization, and certification policy
• National Medical Products Administration (NMPA) — responsible for approving medical devices, pharmaceuticals, cosmetics, and IVD products
• Center for Medical Device Evaluation (CMDE) — responsible for the technical review of Class II and Class III IVD applications.

The regulatory framework is supported by multiple layers of legislation and technical guidance, including administrative measures for medical device registration, classification catalogues, clinical evaluation guidelines, and Good Manufacturing Practice (GMP) requirements.

Standards also play a central role in the regulatory system. IVD products must comply with applicable GB (national standards) and YY (industry standards), which define testing requirements, performance indicators, and technical specifications.

Classification of In Vitro Diagnostic Reagents

Before submitting an application for registration, manufacturers must determine the correct classification of the IVD product.

China categorizes IVDs into three risk classes:

• Class I — Low risk
• Class II — Moderate risk
• Class III — High risk.

Classification is determined based on factors such as:

• intended use of the diagnostic product
• methodology and technology applied
• potential clinical impact of test results
• risk to patients or public health.

The classification determines the regulatory pathway. Class I products follow a filing process, while Class II and Class III products require full technical review and registration.

Manufacturers typically consult the official IVD Classification Catalogue, which is periodically updated by the NMPA to reflect new technologies and diagnostic methods.

Registration Pathways for IVD Products

Several regulatory pathways are available to overseas manufacturers depending on product characteristics and clinical circumstances.

Standard Registration Pathway

The standard pathway remains the most common route for foreign manufacturers seeking NMPA approval.

This process involves:

• product classification confirmation
• preparation of technical documentation
• product testing
• clinical evaluation or clinical trials
• technical review by regulatory authorities.

Innovative Device Pathway

IVDs demonstrating novel technical principles and holding Chinese invention patents may qualify for the innovative medical device pathway.

Benefits may include:

• dedicated regulatory reviewers
• increased communication with authorities
• accelerated review timelines.

Priority Review Pathway

Priority review may be granted to products addressing urgent clinical needs, particularly where:

• no equivalent product exists in China
• the product demonstrates clear clinical advantages
• the technology targets rare, pediatric, or geriatric diseases.

Emergency Approval Pathway

During public health emergencies, the NMPA may grant time-limited emergency approvals for diagnostic products urgently required to address public health risks.

Emergency approvals are typically temporary and must later undergo full regulatory review.

Documentation & Technical Requirements

Preparing the registration dossier is one of the most critical stages of the approval process.

Key documentation typically includes:

• product technical requirements (PTR)
• product specifications and user instructions
• manufacturing information and quality documentation
• performance evaluation data
• applicable standards compliance documentation.

The Product Technical Requirements (PTR) document defines the product’s performance indicators and testing scope and forms part of the final registration certificate once approval is granted.

Applications must be prepared in Chinese and submitted together with supporting documentation and technical reports.

Testing & Clinical Evaluation

Most Class II and Class III IVDs must undergo technical testing and clinical evaluation before approval.

Testing requirements typically include:

• type testing conducted in accredited Chinese laboratories
• evaluation against applicable GB and YY standards
• performance validation against product technical requirements.

Testing timelines often range from four to six months, although complex products may require longer evaluation periods.

Clinical evidence requirements depend on the product classification and regulatory context.

Possible clinical evaluation approaches include:

• clinical evaluation reports comparing the product with an approved predicate device
• use of overseas clinical data where appropriate
• clinical trials conducted in Chinese hospitals when necessary.

For certain products listed in official exemption catalogues, clinical trials may not be required.

Post-Market Compliance & Lifecycle Management

Regulatory responsibilities continue after product approval and market entry.

China’s regulatory system places strong emphasis on lifecycle supervision of medical devices and IVD products.

Post-market obligations typically include:

• adverse event monitoring and reporting
• compliance with Good Manufacturing Practice requirements
• regulatory inspections conducted by authorities
• product traceability through the Unique Device Identification (UDI) system.

IVD registration certificates for Class II and Class III products are generally valid for five years, after which renewal applications must be submitted before expiration.

Manufacturers must also submit change applications when significant product modifications occur.

Who Should Read This Whitepaper

This whitepaper is particularly relevant for:

• Manufacturers of in vitro diagnostic reagents planning to enter the Chinese market
• Regulatory affairs professionals responsible for NMPA device submissions
• Diagnostic technology companies developing molecular, immunoassay, or genetic tests
• Quality and compliance teams managing medical device approvals in China
• Market-entry teams evaluating regulatory pathways for IVD products.